Explore the Work We've Done
For over 30 years, Central Texas Clinical Research has worked in collaboration with many reputable companies and community members to perform an array of medical studies in Texas. We’re proud of the discoveries and advancements we’ve made in the medical field, helping professionals develop a better understanding of unique vaccines, diseases, and conditions.
Please view a few of our past clinical trials below:
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16-40 Years of Age.
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo- controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the Prevention of Oral Persistent Infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in Adult Males, 20 to 45 Years of Age.
A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age.
A Phase 2, Non-Randomized, Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus mRNA-1647 Vaccine in Participants Who Completed Study mRNA-1647-P202.
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine with a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection with Symptoms) in Adults Residing with a Person With COVID-19.
24-hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Treated with Natesto Nasal Testosterone Gel. Healthy Males 18 Years of age and Older.
A Phase 3, Randomized, Observer-blinded study to Evaluate the Efficacy, Safety, tolerability, and Immunogenicity of a Modified RNA Vaccine against Influenza compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 years of Age and older.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine with a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Year of Age or Older.
A Phase 2/3, Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF-07321332/Ritonavir in Preventing Symptomatic SARS-COV-2 Infection in Adult Household Contacts of an Individual with Symptomatic COVID-19.
A Double-Blinded, Placebo-controlled, Double Dummy, Multicenter Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on One, Two or Three Oral Glucose-lowering Agents.
A Double-Blinded, Placebo-controlled, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Diet Control Alone or on Diet Control and Metformin Monotherapy.
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age
A phase II, observer-blind, randomized, controlled study to evaluate the immunogenicity and safety of a varicella vaccine at various potencies compared with Varivax, as a first dose, administered in healthy children in their second year of life.
A Phase 2, Two-Part Study (Open Label [Part 1] Followed by Observer-Blind/[Part 2]) to Evaluate the Safety, Tolerability and Effectiveness of mRNA-1273.214
SARS-CoV-2 Vaccine in Participants Aged 12 Weeks to < 6 Months.
A Prospective, Phase 3, Randomized, Multi-Center, Double-Blind Study of the Efficacy, Tolerability and Safety of Oral Sulopernem Etzadroxil/Probenecid versus Oral Ciprofloxacin for Treatment of Uncomplicated Urinary Tract Infections in Adult Women.